Latest Medicinal Cannabis News

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

Bioxyne Ltd has secured a manufacturing agreement with global cannabis giant Aurora Cannabis, marking a major step in its international expansion of pharmaceutical-grade medicinal cannabis products.

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.